Trihexyphenidyl

CHEMBL1490 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

301.5 g/mol

LogP

4.5

Phase

4

Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the striatum, restoring dopamine-acetylcholine balance disrupted by nigrostriatal dopamine depletion in Parkinson's disease and drug-induced parkinsonism. It is used to reduce tremor, rigidity, and sialorrhea in Parkinson's disease and for treatment of extrapyramidal symptoms caused by antipsychotic medications. Its CNS anticholinergic effects can cause cognitive impairment, hallucinations, and confusion, particularly in elderly patients, limiting its use in modern Parkinson's disease management.

Molekularmasse

301,5000 g/mol

LogP

4,50

TPSA

23,50 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pain Management Schizophrenia Bipolar Disorder Chronic Pain

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1

InChI

InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2

Molecular Formula

C20H31NO

HBD / HBA

1 / 2

Rotierbare Bindungen

5

Schwere Atome

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the striatum, restoring dopamine-acetylcholine balance disrupted by nigrostriatal dopamine depletion in Parkinson's disease and drug-induced parkinsonism. It is used to reduce tremor, rigidity, and sialorrhea in Parkinson's disease and for treatment of extrapyramidal symptoms caused by antipsychotic medications. Its CNS anticholinergic effects can cause cognitive impairment, hallucinations, and confusion, particularly in elderly patients, limiting its use in modern Parkinson's disease management.

Yes, Trihexyphenidyl is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1490. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5572. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Trihexyphenidyl auf PillFYI

Struktur

Schnelldaten

Formel: C20H31NO

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.